Bonanad S, Poveda JL, Gallardo-Escudero J, Haya S, Megias JE, Cid AR, Pérez Alenda S, Casado MA
Programa de acceso a pacientes con efmoroctocog alfa (FVIII recombinante-vida media extendida) para profilaxis en hemofilia a en el Hospital Universitari I Politècnic La Fe
LXI Congreso Nacional de la SEHH y el XXXV Congreso Nacional de la SETH. Valencia. 24-26 oct 2019
Gallardo-Escudero J, Gómez-Barrera M, Becares Martínez FJ, Jarque Ramos I, Gironella Mesa M, Poveda Andrés JL, Martínez Sesmero JM, Oyagüez I
Análisis de Minimización de Costes de un biosimilar de rituximab frente rituximab de referencia en el ámbito de la Oncohematología
64º Congreso de la Sociedad Española Farmacia Hospitalaria (SEFH). Sevilla. 17-19 oct 2019
Jiménez-Yuste V, Álvarez-Román MT, Mingot-Castellano ME, Fernández-Mosteirín N, Mareque M, Oyagüez I
Análisis de costes del tratamiento para pacientes con hemofilia A con inhibidor en España
PharmacoEcon Span Res Artic. 2018;15(1):25-34
Casado LF, Hernández JA, Jarque I, Echave M, Casado MA, Castro A
Cost-utility of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia
20th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Glasgow, Scotland. 4-8 nov 2017
Casado LF, Hernandez JA, Jarque I, Echave M, Casado MA, Castro A
Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia
Eur J Haematol. 2018;100:264–272
Torres C, Oyagüez I, Álvarez MT, Canaro M, Parra R, García JP, Casado MA
Estimation of annual bleeding management cost in severe haemophilia A patients, without inhibitors, in Spain
World Federation of Hemophilia WFH 2016 World Congress. Orlando, EEUU. 24-28 jul 2016
Sabater E, Oyagüez I, Martin M, Bonanad S, Nuñez R, García JP, Casado MA
Long-term Health outcomes comparison between prophylaxis and on-demand treatment in patients with severe haemophilia A with factor VIII inhibitors
World Federation of Hemophilia WFH 2016 World Congress. Orlando, EEUU. 24-28 jul 2016
Sabater E, López-Guillermo A, Rueda A, Salar A, Oyagüez I, Collar JM
Cost-effectiveness analysis of bendamustine plus rituximab as a first-line treatment for patients with follicular lymphoma in Spain
Appl Health Econ Health Policy 2016;14(4):465-77
Villarrubia R, Oyagüez I, Alvarez-Roman MT, Mingot-Castellano ME, Parra R, Casado MA